Log in

NASDAQ:EPZM - Epizyme Stock Price, Forecast & News

-1.17 (-5.41 %)
(As of 02/28/2020 04:00 AM ET)
Today's Range
Now: $20.47
50-Day Range
MA: $23.44
52-Week Range
Now: $20.47
Volume826,700 shs
Average Volume1.14 million shs
Market Capitalization$1.86 billion
P/E RatioN/A
Dividend YieldN/A
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EPZM



Sales & Book Value

Annual Sales$23.80 million
Book Value$2.94 per share


Net Income$-123,630,000.00
Net Margins-715.53%


Market Cap$1.86 billion
Next Earnings Date5/4/2020 (Estimated)

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) issued its quarterly earnings results on Monday, February, 24th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.08. The biopharmaceutical company had revenue of $4.29 million for the quarter, compared to analysts' expectations of $2.83 million. Epizyme had a negative return on equity of 58.35% and a negative net margin of 715.53%. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

7 brokerages have issued 1 year price targets for Epizyme's shares. Their forecasts range from $18.00 to $36.00. On average, they expect Epizyme's stock price to reach $30.50 in the next twelve months. This suggests a possible upside of 49.0% from the stock's current price. View Analyst Price Targets for Epizyme.

What is the consensus analysts' recommendation for Epizyme?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Has Epizyme been receiving favorable news coverage?

News coverage about EPZM stock has trended positive on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Epizyme earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Epizyme.

Are investors shorting Epizyme?

Epizyme saw a increase in short interest in January. As of January 15th, there was short interest totalling 8,780,000 shares, an increase of 9.5% from the December 31st total of 8,020,000 shares. Based on an average daily trading volume, of 919,900 shares, the short-interest ratio is presently 9.5 days. Currently, 11.5% of the company's shares are short sold. View Epizyme's Current Options Chain.

Who are some of Epizyme's key competitors?

What other stocks do shareholders of Epizyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Amarin (AMRN), Clovis Oncology (CLVS), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Novavax (NVAX), TG Therapeutics (TGTX) and Verastem (VSTM).

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
  • Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (6.75%), Victory Capital Management Inc. (2.91%), Victory Capital Management Inc. (2.73%), State Street Corp (2.71%), FMR LLC (2.45%) and Loomis Sayles & Co. L P (1.76%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Institutional Ownership Trends for Epizyme.

Which institutional investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, FMR LLC, State Street Corp, Palo Alto Investors LP, UBS Group AG, Rafferty Asset Management LLC, Goldman Sachs Group Inc. and Citigroup Inc.. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Insider Buying and Selling for Epizyme.

Which institutional investors are buying Epizyme stock?

EPZM stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., Victory Capital Management Inc., State of New Jersey Common Pension Fund D, Candriam Luxembourg S.C.A., Delta Investment Management LLC, EAM Investors LLC and Geode Capital Management LLC. View Insider Buying and Selling for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $20.47.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.86 billion and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

What is Epizyme's official website?

The official website for Epizyme is http://www.epizyme.com/.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]

MarketBeat Community Rating for Epizyme (NASDAQ EPZM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  351 (Vote Underperform)
Total Votes:  803
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel